DALLAS--(BUSINESS WIRE)--Peloton Therapeutics, Inc., a clinical-stage pharmaceutical company advancing first-in-class oral medicines for cancer and other serious conditions, announced today that John Moore has joined the Company as General Counsel and Corporate Secretary. He reports to John A. Josey, Ph.D., Peloton’s Chief Executive Officer (CEO) in this newly created role.
“We are very pleased to welcome John to our executive management team at this pivotal time when our HIF-2α inhibitor programs are maturing,” said John Josey. “He brings to Peloton exceptional business and legal leadership experience representing both private and public companies in the biotechnology and pharmaceutical sector, and his guidance will be greatly valued as we continue to execute on our strategy.”
Mr. Moore has more than 25 years of experience guiding private and public life sciences firms through sensitive business and legal complexity relating to revenue generation and industry alliances, intellectual property matters and corporate governance functions. Prior to joining Peloton, Mr. Moore served as Vice President, General Counsel and Secretary of Array BioPharma Inc., where he facilitated the generation of significant revenue through foreign and domestic collaborations and strategic alliances and strengthened the transactional execution capabilities of the company. He also oversaw corporate governance activities and intellectual property matters for more than 20 drug discovery development programs. He has served on the Board of Directors for Nivalis Therapeutics, Inc. Earlier in his career, Mr. Moore was an attorney for Wilson Sonsini Goodrich & Rosati.
Mr. Moore is educated in Law and Science. He earned a J.D. degree from the University of North Carolina at Chapel Hill School of Law, a M.S. in Biochemistry from the University of Illinois at Urbana-Champaign, and a B.S. in Chemistry from the University of North Carolina at Chapel Hill.
Mr. Moore strengthens Peloton’s legal expertise in corporate matters and management of intellectual assets, rounding out the company’s highly-seasoned management team of scientific, clinical, regulatory and operational experts.
Peloton’s drug discovery and development efforts focus on identifying novel compounds capable of modulating complex protein-protein interactions that drive disease which have eluded conventional small molecule approaches. The company is currently evaluating PT2977, a once-daily oral inhibitor of HIF-2α in an international Phase 2 trial in VHL-associated renal cell carcinoma (RCC), and a Phase 1 trial for the treatment of RCC.
About Peloton Therapeutics
Peloton Therapeutics, Inc. is a clinical-stage pharmaceutical company that is translating groundbreaking scientific insights into first-in-class oral medicines for patients with cancer and other serious or life-threatening conditions. The company’s lead development program is evaluating the only clinical-stage small-molecule inhibitor of hypoxia-inducible factor-2α (HIF-2α), a transcription factor implicated in the development and progression of kidney cancer and a wide variety of other disorders. Peloton is also progressing several research programs by building upon its success in inhibiting HIF-2α which was previously thought to be intractable using small molecules.
To learn more about Peloton Therapeutics, visit www.pelotontherapeutics.com.
© 2018 Peloton Therapeutics, Inc.
All Rights Reserved
